Monitoring and treatment of minimal residual cancer of the prostate

In manifest prostatic carcinoma, partial and complete remissions are obtained in 14-44% of patients as judged by different sets of criteria, but in up to 61% as judged by a decrease in prostatic acid phosphatase. Moreover, this decrease is poorly correlated to that of prostatic size. Prostatic acid...

Full description

Saved in:
Bibliographic Details
Published inBulletin de la Société des sciences médicales du Grand-Duché de Luxembourg Vol. 126; no. 1; p. 65
Main Authors Mathé, G, Schally, A V, Comaru-Schally, A M, Mauvernay, R Y, Vovan, M L, Machover, D, Misset, J L, Court, B, Bouchard, P, Duchier, J
Format Journal Article
LanguageEnglish
Published Luxembourg 01.03.1989
Subjects
Adenocarcinoma - diagnosis
Adenocarcinoma - therapy
Alkaline Phosphatase - analysis
Biomarkers, Tumor - analysis
Combined Modality Therapy
Follow-Up Studies
Humans
Lipids - analysis
Male
N-Acetylneuraminic Acid
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - therapy
Sialic Acids - analysis
Triptorelin Pamoate
Online AccessGet more information

Cover

More Information
Summary:In manifest prostatic carcinoma, partial and complete remissions are obtained in 14-44% of patients as judged by different sets of criteria, but in up to 61% as judged by a decrease in prostatic acid phosphatase. Moreover, this decrease is poorly correlated to that of prostatic size. Prostatic acid phosphatase is therefore considered to be a relatively non-specific tumor marker. A complete remission, i.e. a stage of minimal residual disease, is obtained in about 25% of the patients. Continued endocrine treatment involves the risk of a flare-up of the disease, which is probably small. Additionally, in minimal residual disease, prolonged maintenance treatment requires minimization of side effects. D-Trp-6-LH-RH appears to lead to less gynecomastia and thromboembolism than some other forms of adjuvant therapy.
ISSN:0037-9247